The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Cytokine Growth Factor Rev
; 54: 51-62, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-637561
ABSTRACT
Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response. This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuses on the potential efficacy of ruxolitinib in this infection. The potential targets of ruxolitinib were determined by using genetic alterations that have been reported in COVID-19 patients. The potential effectiveness of ruxolitinib is suggested by evaluating the interactions of these potential targets with ruxolitinib or JAK/STAT pathway.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Pneumonia, Viral
/
Pyrazoles
/
Coronavirus Infections
/
Janus Kinase 1
/
Janus Kinase 2
/
Janus Kinase Inhibitors
Type of study:
Experimental Studies
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Cytokine Growth Factor Rev
Journal subject:
Allergy and Immunology
/
Biochemistry
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS